Cingulate Inc. (CING)
NASDAQ · Manufacturing · Pharmaceutical preparations
CING price, last 12 months
Key stats
- Previous close
- $5.06
- Open
- $5.01
- Day range
- $4.80 – $5.12
- 52-week range
- $3.16 – $11.89
- Volume
- 149.5K
- Avg volume (20 days)
- 98.6K
- Market cap
- $70.2M
Performance
Technicals and fundamentals
About Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $70.2M